Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MTND2P25, or mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 pseudogene 25, is classified as a **pseudogene** in the human genome[2][4][9]. It shares sequence similarity with MT-ND2, a protein-coding mitochondrial gene critical for the function of mitochondrial respiratory chain Complex I[1][3][8]. MTND2P25 itself **does not encode a functional protein** and is not associated with canonical mitochondrial electron transport or ATP synthesis. There is currently no evidence for its direct involvement in known biological processes, disease mechanisms, or as a therapeutic target. No drugs, biomarkers, or mechanisms of action are associated with it, and it is not considered a target for therapy. Its presence mainly reflects the existence of non-functional, nuclear-encoded sequences derived from mitochondrial genes, commonly designated as NUMTs (nuclear mitochondrial DNA segments)[2][4][9]. The gene is recorded at HGNC:42126 and NCBI Gene:100873231[2][4][9]. MTND2P25 should not be confused with the functional mitochondrial gene MT-ND2 or its protein product NADH dehydrogenase 2[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 pseudogene 25 (MTND2P25).